Research priorities in spasmodic dysphonia [PDF]
ObjectiveTo identify research priorities to increase understanding of the pathogenesis, diagnosis, and improved treatment of spasmodic dysphonia.Study Design and SettingA multidisciplinary working group was formed that included both scientists and clinicians from multiple disciplines (otolaryngology, neurology, speech pathology, genetics, and ...
Laryngeal and Speech Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD ( host institution ) +15 more
core +6 more sources
Do We Cause Dysphagia When Treating Spasmodic Dysphonia with Botox?
Objective: Spasmodic dysphonia (SD) is a neurological movement disorder involving the laryngeal muscles. There are three main types: adductor, abductor, and mixed type. Adductor type is the most common and mixed type is the rarest.
Esma Altan +3 more
doaj +2 more sources
Vocal aging and adductor spasmodic dysphonia: Response to botulinum toxin injection
Michael P Cannito, Joel C Kahane, Lesya ChornaSchool of Audiology and Speech-Language Pathology, The University of Memphis, Memphis, TN, USAAbstract: Aging of the larynx is characterized by involutional changes which alter its biomechanical and neural ...
Michael P Cannito +2 more
doaj +2 more sources
Transnasal Endoscopic Injection of Botulinum Toxin in Patients with Adductor Spasmodic Dysphonia [PDF]
Introduction:Adductor Spasmodic Dysphonia (ADSD) is the most common form of spasmodic dysphonia. It encompasses various symptoms affecting voice and speech.
Abdul-Latif Hamdan +3 more
doaj +2 more sources
Retrospective review of dosing trends in botulinum toxin injections for the treatment of adductor spasmodic dysphonia in a long-term cohort [PDF]
Background Botulinum toxin A (BT) is the gold standard treatment for adductor spasmodic dysphonia (AdSD) with established use for greater than thirty years.
Gabrielle French +2 more
doaj +2 more sources
Post‐treatment clinical course following botulinum toxin injection therapy for adductor spasmodic dysphonia: Analysis of data from a placebo‐controlled, randomized, double‐blinded clinical trial in Japan [PDF]
Objective Botulinum toxin (BT) therapy is a first‐line treatment for spasmodic dysphonia (SD). However, a detailed chronological course and clinical factors that affect the therapeutic effect have been vague.
Kahori Hirose +7 more
doaj +2 more sources
Botulinum toxin efficacy in the treatment of patients with spasmodic dysphonia [PDF]
Background/Aim. Spasmodic dysphonia (DS) is a disabling speech disturbance appearing as the consequence of dystonic vocal folds contraction. Its intermittent appearance in the laryngeal muscles causes vocal function discontinuation.
Svetel Marina +10 more
doaj +3 more sources
Transcranial magnetic stimulation and functional magnet resonance imaging evaluation of adductor spasmodic dysphonia during phonation [PDF]
Background: Reduced intracortical inhibition is a neurophysiologic finding in focal dystonia that suggests a broader problem of impaired cortical excitability within the brain.
Mo Chen +6 more
doaj +2 more sources
Spasmodic dysphonia: description of the disease and associated neurologic disorders
Introduction: Spasmodic dysphonia (SD) is a problem that affects speech and vocalization, one of the most devastating disorders of oral communication. It is characterized by vocal quality tensaestrangulada, harshly and / or interspersed with abrupt vocal
Coelho, Marina Serrato +5 more
doaj +1 more source
Demographics and coexisting tremor, cervical dystonia and vocal fold disorders in a group of patients with spasmodic dysphonia [PDF]
Selmin Karatayli Ozgursoy +3 more
doaj +2 more sources

